Actively Recruiting
Minimal Vitrectomy Surgery Versus Conventional Vitrectomy for Idiopathic Epiretinal Membrane Treatment: A Multicenter Randomized Controlled Trial
Led by Peking Union Medical College Hospital · Updated on 2025-06-13
140
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Peking Union Medical College Hospital
Lead Sponsor
P
Peking Union Medical College
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to compare two surgical methods for idiopathic epiretinal membrane (ERM), a condition where abnormal cell growth on the retina causes swelling, distorted vision, and visual loss. The trial evaluates Minimal Vitrectomy Surgery (MVS), a newer approach designed to reduce the amount of vitreous removed during surgery, against the conventional vitrectomy method. The study focuses on improvements in visual acuity and cataract progression over 12 months. Participants will receive either Minimal Vitrectomy Surgery, where the membrane is peeled through the intact vitreous and limited vitrectomy is selectively done if floaters or membrane fragments remain, or conventional vitrectomy involving standard removal of vitreous and membrane peeling. The study is randomized and conducted across multiple centers, with each surgical method carefully defined and monitored. During the trial, participants will undergo assessments including visual acuity tests, cataract evaluations using LOCS III and DLI, and measurements of central retinal thickness by OCT. These evaluations occur from baseline through intervals up to 12 months. Researchers will also monitor for membrane recurrence and surgical complications. The total participation includes a follow-up period of one year after surgery.
CONDITIONS
Brief Title
Minimal Vitrectomy Surgery for Epiretinal Membrane
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed diagnosis of idiopathic epiretinal membrane by clinical examination and OCT imaging
- Clear ocular media allowing quality fundus imaging
- Phakic eye (natural lens present)
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Prior cataract surgery or advanced cataract requiring combined surgery
- Presence of other retinal diseases such as diabetic retinopathy, retinal detachment, or retinal vein occlusion
- Systemic health conditions that prevent safe surgery or follow-up
- History of prior ocular or periocular corticosteroid use, including injections or long-term eye drops for the eyes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo either Minimal Vitrectomy Surgery or Conventional Vitrectomy to treat idiopathic epiretinal membrane.
1 surgery visit (in-person)
Duration - 12 months
Participants are followed after surgery to monitor vision improvement, macular thickness, cataract progression, and possible membrane recurrence.
Follow-up visits at 1 week, 1 month, 3 months, 6 months, and 12 months (in-person)
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
W
Weihong Yu, MD
X
Xufeng Zhao
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here